IMMUNOLOGICALLY DISTINCT CELL SURFACE VARIANTS FOR CELL THERAPY APPLICATIONS Russian patent published in 2023 - IPC C12Q1/68 C12N15/10 C12N15/90 C12N5/783 

FIELD: biotechnology, genetic engineering.

SUBSTANCE: method for selectively depleting cells expressing the second isoform of a surface protein in vivo. To implement the method, first, a human hematopoietic cell is injected into the patient, which expresses the first isoform of the specified surface protein, which is functionally indistinguishable but immunologically distinct from the second isoform of said surface protein. Then the patient is injected with an antibody or antibody-like molecule that is specifically reactive with the second isoform of said surface protein to ablate the cell expressing the said second isoform. Then there is selective depletion of cells expressing the second isoform of said surface protein based on the expression of the second isoform of said surface protein. Said cell is administered prior to, during or after specific ablation of cells expressing said second isoform of said surface protein. And said surface protein contains an extracellular polypeptide sequence, and said first isoform contains an insertion, deletion and/or substitution of 1, 2, 3, 4 or 5 amino acids compared to said second isoform.

EFFECT: providing a system that serves to permanently label and track cells and selectively deplete labeled or unlabeled cells in vitro or in vivo.

8 cl, 32 dwg, 1 ex